Literature DB >> 20562007

Signal transduction pathways associated with ATP-induced proliferation of colon adenocarcinoma cells.

Natalia Buzzi1, Ricardo Boland, Ana Russo de Boland.   

Abstract

BACKGROUND: In previous work, we have demonstrated that extracellular adenosine 5'-triphosphate (ATP) acts on intestinal Caco-2 cell P2Y receptors promoting a rapid increase in the phosphorylation of ERK1/2, p46 JNK and p38 MAP kinases (MAPKs). METHODS AND
RESULTS: In this study, we investigated whether the extracellular ATP-P2Y receptor signalling pathways were required for the proliferation of Caco-2 cells. Confocal microscopy and immunobloting studies showed that ERK1/2 and JNK translocate into the nucleus of the cells stimulated by ATP, where they participate, together with p38 MAPK, in the phosphorylation of JunD, ATF-1 and ATF-2 transcription factors. In addition, ATP through the activation of MAPKs induces the expression of the immediate early genes products of the Jun family, c-Fos and MAP kinase phosphatase-1 (MKP-1). Moreover, ERK1/2 and p38 MAPK are involved in the phosphorylation of MKP-1 in Caco-2 cells. Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively.
CONCLUSION: Extracellular ATP induces proliferation of Caco-2 human colonic cancer cells by activating MAPK cascades and modulation of transcription factors. GENERAL SIGNIFICANCE: These findings and identification of the specific P2Y subtype receptors involved in the mitogenic effect of ATP on Caco-2 cells might be relevant for understanding tumor cell development, resistance to treatment regimens and the design of new therapeutic strategies.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562007     DOI: 10.1016/j.bbagen.2010.05.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Reviewing the role of P2Y receptors in specific gastrointestinal cancers.

Authors:  Steve Dagenais Bellefeuille; Caroline M Molle; Fernand-Pierre Gendron
Journal:  Purinergic Signal       Date:  2019-09-02       Impact factor: 3.765

Review 2.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

3.  The Expression Level of ABCC6 Transporter in Colon Cancer Cells Correlates with the Activation of Different Intracellular Signaling Pathways.

Authors:  Vittorio Abruzzese; Caecilia H C Sukowati; Claudio Tiribelli; Ilenia Matera; Angela Ostuni; Faustino Bisaccia
Journal:  Pathophysiology       Date:  2022-05-12

Review 4.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

5.  Multidrug Resistance-Associated Protein 2 Expression Is Upregulated by Adenosine 5'-Triphosphate in Colorectal Cancer Cells and Enhances Their Survival to Chemotherapeutic Drugs.

Authors:  Valérie Vinette; Morgane Placet; Guillaume Arguin; Fernand-Pierre Gendron
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

Review 6.  Important roles of P2Y receptors in the inflammation and cancer of digestive system.

Authors:  Han-Xing Wan; Jian-Hong Hu; Rei Xie; Shi-Ming Yang; Hui Dong
Journal:  Oncotarget       Date:  2016-05-10

7.  ATP-P2Y2-β-catenin axis promotes cell invasion in breast cancer cells.

Authors:  Jiang-Lan Zhang; Ying Liu; Hui Yang; Hong-Quan Zhang; Xin-Xia Tian; Wei-Gang Fang
Journal:  Cancer Sci       Date:  2017-06-06       Impact factor: 6.716

8.  Extracellular nucleotides as novel, underappreciated pro-metastatic factors that stimulate purinergic signaling in human lung cancer cells.

Authors:  Gabriela Schneider; Talita Glaser; Claudiana Lameu; Ahmed Abdelbaset-Ismail; Zachariah Payne Sellers; Marcin Moniuszko; Henning Ulrich; Mariusz Z Ratajczak
Journal:  Mol Cancer       Date:  2015-11-24       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.